CompletedNot Applicable

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Austria, Belgium, Czechia119 participantsStarted 2007-01

Plain-language summary

RATIONALE: Studying biopsy, bone marrow, and blood samples from patients with cytopenia that did not respond to treatment may help doctors learn more about the disease and plan the best treatment. PURPOSE: This laboratory study is assessing immune function in young patients with cytopenia that did not respond to treatment.

Who can participate

Age range17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of refractory cytopenia (RC) including any of the following: * Severe aplastic anemia (SAA) * Fanconi's anemia * Shwachman Diamond syndrome * Dyskeratosis congenita * Pearson syndrome * All RC patients included in the EWOG MDS 2006 protocol irrespective of therapy * Patients who have undergone hematopoietic stem cell transplantation (HSCT) may be enrolled on EWOG-MDS SCT RC RIC 06 or EWOG-MDS SCT MDS 06 protocol PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * No prior immunosuppressive therapy for refractory cytopenia

What they're measuring

Number of patients with TCR V beta oligoclonality at diagnosis

Timeframe: 96 months

Immunophenotype of patients with oligoclonal T-cell expansion

Timeframe: 96 months

Number of patients with glycophosphatidylinositol (GPI) deficient clones

Timeframe: 96 months

Trial details

NCT IDNCT00499070

SponsorUniversity Hospital Freiburg

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2012-08

View on ClinicalTrials.gov More Dyskeratosis Congenita trials